• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

玻璃体内注射透明质酸包被的脂质复合物包裹的小干扰RNA的神经保护作用

Neuroprotective Effect of siRNA Entrapped in Hyaluronic Acid-Coated Lipoplexes by Intravitreal Administration.

作者信息

Ribeiro Marcela Coelho Silva, de Miranda Marcelo Coutinho, Cunha Pricila da Silva, Andrade Gracielle Ferreira, Fulgêncio Gustavo de Oliveira, Gomes Dawidson Assis, Fialho Sílvia Ligorio, Pittella Frederico, Charrueau Christine, Escriou Virginie, Silva-Cunha Armando

机构信息

Faculdade de Farmácia, Universidade Federal de Minas Gerais, 31270-901 Belo Horizonte, Brazil.

Université de Paris, CNRS, INSERM, UTCBS, Unité des Technologies Chimiques et Biologiques pour la Santé, 75006 Paris, France.

出版信息

Pharmaceutics. 2021 Jun 8;13(6):845. doi: 10.3390/pharmaceutics13060845.

DOI:10.3390/pharmaceutics13060845
PMID:34200993
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8226864/
Abstract

Since the possibility of silencing specific genes linked to retinal degeneration has become a reality with the use of small interfering RNAs (siRNAs), this technology has been widely studied to promote the treatment of several ocular diseases. Despite recent advances, the clinical success of gene silencing in the retina is significantly reduced by inherent anatomical and physiological ocular barriers, and new strategies are required to achieve intraocular therapeutic effectiveness. In this study, we developed lipoplexes, prepared with sodium alginate as an adjuvant and strategically coated with hyaluronic acid (HA-LIP), and investigated the potential neuroprotective effect of these systems in a retinal light damage model. Successful functionalization of the lipoplexes with hyaluronic acid was indicated in the dynamic light scattering and transmission electron microscopy results. Moreover, these HA-LIP nanoparticles were able to protect and deliver siRNA molecules targeting caspase-3 into the retina. After retinal degeneration induced by high light exposure, in vitro and in vivo quantitative reverse transcription-PCR (RT-qPCR) assays demonstrated significant inhibition of caspase-3 expression by HA-LIP. Furthermore, these systems were shown to be safe, as no evidence of retinal toxicity was observed by electroretinography, clinical evaluation or histology.

摘要

由于使用小干扰RNA(siRNA)使沉默与视网膜变性相关的特定基因成为可能,这项技术已被广泛研究以促进多种眼部疾病的治疗。尽管取得了最新进展,但视网膜基因沉默的临床成功率因眼部固有的解剖和生理屏障而显著降低,因此需要新的策略来实现眼内治疗效果。在本研究中,我们开发了以海藻酸钠为佐剂并经透明质酸策略性包被的脂质体复合物(HA-LIP),并在视网膜光损伤模型中研究了这些系统的潜在神经保护作用。动态光散射和透射电子显微镜结果表明脂质体复合物成功用透明质酸功能化。此外,这些HA-LIP纳米颗粒能够保护并将靶向半胱天冬酶-3的siRNA分子递送至视网膜。在高光暴露诱导视网膜变性后,体外和体内定量逆转录聚合酶链反应(RT-qPCR)分析表明HA-LIP对半胱天冬酶-3表达有显著抑制作用。此外,这些系统被证明是安全的,因为通过视网膜电图、临床评估或组织学未观察到视网膜毒性的证据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f089/8226864/917fee318806/pharmaceutics-13-00845-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f089/8226864/1d73f930586f/pharmaceutics-13-00845-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f089/8226864/239bc6c9bd55/pharmaceutics-13-00845-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f089/8226864/b3ad40ad74bf/pharmaceutics-13-00845-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f089/8226864/e1527cd4f3b1/pharmaceutics-13-00845-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f089/8226864/093d7148fc6f/pharmaceutics-13-00845-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f089/8226864/917fee318806/pharmaceutics-13-00845-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f089/8226864/1d73f930586f/pharmaceutics-13-00845-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f089/8226864/239bc6c9bd55/pharmaceutics-13-00845-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f089/8226864/b3ad40ad74bf/pharmaceutics-13-00845-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f089/8226864/e1527cd4f3b1/pharmaceutics-13-00845-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f089/8226864/093d7148fc6f/pharmaceutics-13-00845-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f089/8226864/917fee318806/pharmaceutics-13-00845-g006.jpg

相似文献

1
Neuroprotective Effect of siRNA Entrapped in Hyaluronic Acid-Coated Lipoplexes by Intravitreal Administration.玻璃体内注射透明质酸包被的脂质复合物包裹的小干扰RNA的神经保护作用
Pharmaceutics. 2021 Jun 8;13(6):845. doi: 10.3390/pharmaceutics13060845.
2
Effect of hyaluronic acid-binding to lipoplexes on intravitreal drug delivery for retinal gene therapy.透明质酸与脂质体复合物结合对视网膜基因治疗玻璃体内药物递送的影响。
Eur J Pharm Sci. 2017 May 30;103:27-35. doi: 10.1016/j.ejps.2017.02.027. Epub 2017 Feb 20.
3
Hyaluronic acid coating of gold nanoparticles for intraocular drug delivery: Evaluation of the surface properties and effect on their distribution.用于眼内药物递送的金纳米颗粒的透明质酸涂层:表面性质评估及其对分布的影响
Exp Eye Res. 2020 Sep;198:108151. doi: 10.1016/j.exer.2020.108151. Epub 2020 Jul 25.
4
Hyaluronic acid-conjugated lipoplexes for targeted delivery of siRNA in a murine metastatic lung cancer model.透明质酸偶联脂质体用于在小鼠转移性肺癌模型中靶向递送 siRNA。
Int J Pharm. 2016 Nov 30;514(1):103-111. doi: 10.1016/j.ijpharm.2016.06.125.
5
The obstacle course to the inner retina: Hyaluronic acid-coated lipoplexes cross the vitreous but fail to overcome the inner limiting membrane.内视网膜的障碍:透明质酸包被的脂质体穿过玻璃体,但无法克服内界膜。
Eur J Pharm Biopharm. 2019 Aug;141:161-171. doi: 10.1016/j.ejpb.2019.05.023. Epub 2019 May 28.
6
Coating nanocarriers with hyaluronic acid facilitates intravitreal drug delivery for retinal gene therapy.用透明质酸包覆纳米载体有助于视网膜基因治疗的玻璃体内药物递送。
J Control Release. 2015 Mar 28;202:83-92. doi: 10.1016/j.jconrel.2015.01.030. Epub 2015 Jan 26.
7
Nanosystems based on siRNA silencing HuR expression counteract diabetic retinopathy in rat.基于小干扰RNA(siRNA)沉默HuR表达的纳米系统可对抗大鼠糖尿病视网膜病变。
Pharmacol Res. 2016 Sep;111:713-720. doi: 10.1016/j.phrs.2016.07.042. Epub 2016 Jul 27.
8
HMGB1 siRNA can reduce damage to retinal cells induced by high glucose in vitro and in vivo.高迁移率族蛋白B1(HMGB1)小干扰RNA(siRNA)在体内外均可减轻高糖对视网膜细胞造成的损伤。
Drug Des Devel Ther. 2017 Mar 15;11:783-795. doi: 10.2147/DDDT.S129913. eCollection 2017.
9
In vivo siRNA delivery system for targeting to the liver by poly-l-glutamic acid-coated lipoplex.通过聚-L-谷氨酸包被的脂质复合物靶向肝脏的体内小干扰RNA递送系统。
Results Pharma Sci. 2014 Jan 25;4:1-7. doi: 10.1016/j.rinphs.2014.01.001. eCollection 2014.
10
Hyaluronic Acid-Based Gold Nanoparticles for the Topical Delivery of Therapeutics to the Retina and the Retinal Pigment Epithelium.用于将治疗药物局部递送至视网膜和视网膜色素上皮的基于透明质酸的金纳米颗粒。
Polymers (Basel). 2021 Sep 28;13(19):3324. doi: 10.3390/polym13193324.

引用本文的文献

1
Development and Characterization of Modified Chitosan Lipopolyplex for an Effective siRNA Delivery.改性壳聚糖脂质体的研制及其作为有效 siRNA 递药系统的特性研究。
AAPS PharmSciTech. 2024 Jan 8;25(1):13. doi: 10.1208/s12249-023-02728-z.
2
Next-Generation Nanomedicine Approaches for the Management of Retinal Diseases.用于视网膜疾病治疗的新一代纳米医学方法。
Pharmaceutics. 2023 Jul 22;15(7):2005. doi: 10.3390/pharmaceutics15072005.
3
Nanotechnology-based ocular drug delivery systems: recent advances and future prospects.基于纳米技术的眼部药物传递系统:最新进展与未来展望。

本文引用的文献

1
Avoiding the Pitfalls of siRNA Delivery to the Retinal Pigment Epithelium with Physiologically Relevant Cell Models.利用生理相关细胞模型避免向视网膜色素上皮细胞递送小干扰RNA的陷阱
Pharmaceutics. 2020 Jul 16;12(7):667. doi: 10.3390/pharmaceutics12070667.
2
Binding and Internalization in Receptor-Targeted Carriers: The Complex Role of CD44 in the Uptake of Hyaluronic Acid-Based Nanoparticles (siRNA Delivery).受体靶向载体的结合和内化:CD44 在透明质酸基纳米颗粒(siRNA 递呈)摄取中的复杂作用
Adv Healthc Mater. 2019 Dec;8(24):e1901182. doi: 10.1002/adhm.201901182. Epub 2019 Nov 18.
3
The obstacle course to the inner retina: Hyaluronic acid-coated lipoplexes cross the vitreous but fail to overcome the inner limiting membrane.
J Nanobiotechnology. 2023 Jul 22;21(1):232. doi: 10.1186/s12951-023-01992-2.
4
Advances in Ocular Drug Delivery Systems.眼部给药系统的进展
Pharmaceutics. 2021 Sep 1;13(9):1383. doi: 10.3390/pharmaceutics13091383.
内视网膜的障碍:透明质酸包被的脂质体穿过玻璃体,但无法克服内界膜。
Eur J Pharm Biopharm. 2019 Aug;141:161-171. doi: 10.1016/j.ejpb.2019.05.023. Epub 2019 May 28.
4
Modifying internal organization and surface morphology of siRNA lipoplexes by sodium alginate addition for efficient siRNA delivery.通过添加海藻酸钠来修饰 siRNA 脂质体的内部结构和表面形态,以实现高效的 siRNA 递送。
J Colloid Interface Sci. 2019 Mar 22;540:342-353. doi: 10.1016/j.jcis.2019.01.043. Epub 2019 Jan 14.
5
Application of hyaluronic acid as carriers in drug delivery.透明质酸作为载体在药物传递中的应用。
Drug Deliv. 2018 Nov;25(1):766-772. doi: 10.1080/10717544.2018.1450910.
6
Long non-coding RNA MEG3 silencing protects against light-induced retinal degeneration.长链非编码RNA MEG3沉默可预防光诱导的视网膜变性。
Biochem Biophys Res Commun. 2018 Feb 19;496(4):1236-1242. doi: 10.1016/j.bbrc.2018.01.177. Epub 2018 Feb 1.
7
Molecular genetics and emerging therapies for retinitis pigmentosa: Basic research and clinical perspectives.色素性视网膜炎的分子遗传学和新兴疗法:基础研究与临床视角。
Prog Retin Eye Res. 2018 Mar;63:107-131. doi: 10.1016/j.preteyeres.2017.10.004. Epub 2017 Oct 31.
8
Overcoming ocular drug delivery barriers through the use of physical forces.通过物理作用力克服眼部药物输送障碍。
Adv Drug Deliv Rev. 2018 Feb 15;126:96-112. doi: 10.1016/j.addr.2017.09.008. Epub 2017 Sep 12.
9
Gene therapy for inherited retinal degenerations: initial successes and future challenges.遗传性视网膜退行性疾病的基因治疗:初步成功与未来挑战。
J Neural Eng. 2017 Oct;14(5):051002. doi: 10.1088/1741-2552/aa7a27. Epub 2017 Aug 22.
10
Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial.治疗 RPE65 介导的遗传性视网膜营养不良患者的 voretigene neparvovec(AAV2-hRPE65v2)的疗效和安全性:一项随机、对照、开放标签、3 期临床试验。
Lancet. 2017 Aug 26;390(10097):849-860. doi: 10.1016/S0140-6736(17)31868-8. Epub 2017 Jul 14.